. CML progression usually occurs in three phases, including a chronic phase (CP) that most often is asymptomatic, an accelerated phase (AP), and a terminal blast phase (BP) (Sawyers, 1999) . If CML is left untreated, progression from CP to BP usually occurs in three to five years (Sawyers). CML is characterized by a genetic translocation between chromosomes 9 and 22 (the Philadelphia chromosome). The translocation results in an abnormal fusion gene that encodes for the constitutively active BCR-ABL tyrosine kinase, the known causative agent underlying CML pathogenesis (Daley, Van Etten, & Baltimore, 1990; Faderl et al., 1999) . The identification of this protein has made it an ideal target for therapeutic intervention.
The tyrosine kinase inhibitor (TKI) imatinib was the first BCR-ABL-targeted agent approved in 2001 for the treatment of patients with CML and has revolutionized the treatment of the disease. Unfortunately, resistance to imatinib has become a clinically significant problem that limits the long-term benefits of the drug in many patients with CML (Oestreicher, 2007a) . The mechanisms that underlie imatinib resistance are multifactorial and should be considered carefully when healthcare professionals are choosing second-line treatment. This article discusses the
